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ABSTRACT Gene transfer and homologous recombination in Streptococcus pyogenes
has the potential to trigger the emergence of pandemic lineages, as exempliﬁed by
lineages of emm1 and emm89 that emerged in the 1980s and 2000s, respectively.
Although near-identical replacement gene transfer events in the nga (NADase) and
slo (streptolysin O) loci conferring high expression of these toxins underpinned the
success of these lineages, extension to other emm genotype lineages is unreported.
The emergent emm89 lineage was characterized by ﬁve regions of homologous re-
combination additional to nga-slo, including complete loss of the hyaluronic acid
capsule synthesis locus hasABC, a genetic trait replicated in two other leading emm
types and recapitulated by other emm types by inactivating mutations. We hypothe-
sized that other leading genotypes may have undergone similar recombination
events. We analyzed a longitudinal data set of genomes from 344 clinical invasive
disease isolates representative of locations across England, dating from 2001 to 2011,
and an international collection of S. pyogenes genomes representing 54 different ge-
notypes and found frequent evidence of recombination events at the nga-slo locus
predicted to confer higher toxin genotype. We identiﬁed multiple associations be-
tween recombination at this locus and inactivating mutations within hasAB, suggest-
ing convergent evolutionary pathways in successful genotypes. This included com-
mon genotypes emm28 and emm87. The combination of no or low capsule and
high expression of nga and slo may underpin the success of many emergent S. pyo-
genes lineages of different genotypes, triggering new pandemics, and could change
the way S. pyogenes causes disease.
IMPORTANCE Streptococcus pyogenes is a genetically diverse pathogen, with over
200 different genotypes deﬁned by emm typing, but only a minority of these geno-
types are responsible for the majority of human infection in high-income countries.
Two prevalent genotypes associated with disease rose to international dominance
following recombination of a toxin locus that conferred increased expression. Here,
we found that recombination of this locus and promoter has occurred in other di-
verse genotypes, events that may allow these genotypes to expand in the popula-
tion. We identiﬁed an association between the loss of hyaluronic acid capsule synthesis
and high toxin expression, which we propose may be associated with an adaptive ad-
vantage. As S. pyogenes pathogenesis depends both on capsule and toxin production,
new variants with altered expression may result in abrupt changes in the molecular epi-
demiology of this pathogen in the human population over time.
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The capacity for the bacterial human pathogen Streptococcus pyogenes to undergogenetic exchange, independent of known bacteriophages or mobile elements, is
not well understood, yet recent evidence suggests it underpins the emergence of success-
ful new variants that rapidly rise to international dominance. Homologous recombination
of a chromosomal region encompassing the toxin genes nga (encoding NADase), ifs
(encoding the inhibitor for NADase), and slo (encoding streptolysin O), which was dated
to have occurred in the mid-1980s, is thought to have driven the rise of emm1 to almost
global dominance (1). The homologous recombination event resulted in increased
nga-slo expression compared to that of the previous variant, linked to the gain of a
highly active nga-ifs-slo promoter in the new emm1 variant compared to that of the
previous variant (2).
A very similar recombination event was recently identiﬁed in the genotype emm89.
A new variant of emm89 sequence type (ST) 101 (also referred to as clade 3) emerged,
having undergone six regions of predicted homologous recombination compared to its
ST101 predecessor (also referred to as clade 2) (3, 4). One of the six regions encom-
passed the nga-ifs-slo locus, comprising a region almost identical to that of emm1,
which conferred similarly high expression of nga and slo compared to that of the
previous variant. Another recombination region within the emergent ST101 emm89
resulted in the loss of the hyaluronic acid capsule. We dated the emergence of this new
acapsular high-toxin-expressing ST101 emm89 lineage to the mid-1990s, but there was
a rapid increase and rise to dominance in the United Kingdom between 2005 and 2010
(3). The lineage is now the dominant form of emm89 in the United Kingdom as well as
other parts of the world, including Europe, North America, and Japan (4–8).
Given that recombination associated with nga-ifs-slo can give rise to new successful
S. pyogenes variants, we hypothesized that this may be a feature common to other
successful emm types. To determine if this is the case, we sequenced the genomes of
344 S. pyogenes invasive disease isolates originating from hospitals across England
between 2001 and 2011 and compared the data with other available historical and
contemporary international S. pyogenes whole-genome sequence (WGS) data. We
identiﬁed that recombination of the nga-ifs-slo locus has occurred in other leading emm
types, supporting the hypothesis that it can underpin the emergence and success of
new lineages. We also identiﬁed an association of nga-ifs-slo recombination toward a
high-activity promoter variant with inactivating mutations within the capsule locus.
This suggests that loss of capsule may also provide an advantage to certain genotypes,
either through a direct effect on pathogenesis or an association with the process of
recombination.
RESULTS
Genetic characterization of bacteremia isolates. We performed whole-genome
sequencing of 344 S. pyogenes invasive isolates collected from hospitals across England
by the British Society for Antimicrobial Chemotherapy (BSAC) Bacteraemia Resistance
Surveillance Program from 2001 to 2011. Forty-four different emm types were identiﬁed
from de novo assembly, with the most common being emm1 (n 64, 18.6%), emm12
(n 34, 9.9%), emm89 (n 32, 9.3%), emm3 (n 28, 8.1%), emm87 (n  22, 6.4%), and
emm28 (n 15, 4.4%) (see Fig. S1 in the supplemental material). Antimicrobial suscep-
tibilities were typical for S. pyogenes, with 100% of isolates susceptible to penicillin and
22% resistant to clindamycin, erythromycin, and/or tetracycline; detailed susceptibilities
and associated genotypes are reported in Data Set S1.
The phylogenetic distribution of the 344 isolates based on core genome variation
revealed distinct clustering by emm type, each forming single lineages with the
exceptions of emm44, emm90, and emm101, each of which formed two lineages
(Fig. 1A). Pairwise distances between isolates gave a median of just 45 single nucleotide
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polymorphisms (SNPs) separating the genomes of isolates of the same emm genotype
(range, 0 to 15,137 SNPs) compared to a median of 15,648 SNPs separating the
genomes of isolates of different emm types (range, 5,312 to 18,317 SNPs) (Fig. 1B).
The genotypes emm44, emm90, and emm101 gave the highest SNP distance for the
intra-emm comparison (13,494 to 15,137 SNPs), which approaches the median level
observed between emm types. This indicated that while other genotypes represent a
relatively conserved chromosomal genetic background, the populations of emm44,
emm90, and emm101 exhibit more diverse chromosomal backgrounds despite repre-
senting the same emm type, potentially due to emm gene switching.
High level of variation within the nga-ifs-slo locus. To identify the level of variation
within the nga-ifs-slo locus, we extracted the sequence from the 3= end of nusG
(immediately upstream of nga) to the 3= end of slo (P-nga-ifs-slo), comprising the entire
locus and all of the upstream sequence, including the predicted 67-bp nga-ifs-slo
promoter region (9). We constructed a phylogenetic tree from SNPs within the P-nga-
ifs-slo region from the genomes of isolates belonging to the most common emm types
and compared it to the phylogeny constructed with SNPs extracted from a whole-
genome comparison to a reference emm89 genome, H293 (Fig. 2). Most emm geno-
types were associated with a single P-nga-ifs-slo variant that was unique to that
genotype. The main exception to this was the P-nga-ifs-slo variant found in modern
(post-1980s M1T1) emm1, as this was also found in all emm12, all emm22 (a lineage
known to be acapsular) isolates, and 11 of the 32 emm89 isolates. These 11 emm89
isolates represented the emergent acapsular ST101 variant, while the remaining 21
emm89 isolates represented the original encapsulated ST101 variant, with a different
FIG 1 Low diversity within emm genotypes. (A) A maximum likelihood phylogenetic tree constructed from 113,805 core SNPs extracted after mapping all 344
BSAC isolates to the complete emm89 reference strain H293 (indicated by a star) identiﬁed that the majority of isolates cluster by emm genotype. Exceptions
were emm44, emm90, and emm101 (highlighted with black dots), each of which were present as two separate lineages. Branches are colored based on
bootstrap support (scale bar in ﬁgure). Boxes at branch tips are colored by emm type, and the emm-type numbers are provided outside the tree. (B) As reﬂected
by the phylogenetic tree, the number of SNPs separating isolates was high (5,000) when the genomes of isolates of different emm types were compared (black
bars). This was much lower when comparisons were made between the genomes of isolates of the same emm type (red bars).
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unique P-nga-ifs-slo as previously reported (3). The entire emm75 population and one
of the two emm76 isolates were also associated with a P-nga-ifs-slo variant that was
closely related to the emm1-like variant. All but two emm87 isolates had a P-nga-ifs-slo
variant also found in the acapsular lineage emm4. The presence of multiple P-nga-ifs-slo
FIG 2 Comparison of the variation within the P-nga-ifs-slo region and core chromosome. A maximum likelihood
phylogenetic tree was constructed from 205 SNPs extracted from an alignment of the nga-ifs-slo locus and associated
upstream region to include the promoter (P-nga-ifs-slo) extracted from de novo assemblies of BSAC S. pyogenes collection
(left tree). This was compared to the phylogenetic tree constructed using 75,851 SNPs across the entire core genome after
mapping to the H293 reference genome (right tree). Only 20 of the most common emm genotypes were included: emm1,
-3, -4, -5, -6, -12, -18, -22, -28, -43, -44, -75, -76, -77, -78, -81, -83, -87, -89, and -101 (n 303 isolate genomes). Numbers and
colored blocks on the right tree represent emm types. Variants of the P-nga-ifs-slo are of the same color as the emm type
if unique to that emm type. The P-nga-ifs-slo variant found in emm1 (red) was common to other genotypes of emm12,
emm22, and some emm89 isolates. The genotypes emm76, emm87, and emm89 were linked to more than one variant of
P-nga-ifs-slo. Gray shading indicates high-expressing promoter variants: A27T22T18 (top) or A27G22T18 (bottom).
Other nonshaded areas are low-expressing promoter variants A27T22C18 or G27T22T18. Scale bar represents
substitutions per site. Bootstrap support values are provided on branches.
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variants within the emm76 and emm87 genotypes, where the core chromosome was
otherwise relatively conserved, indicated that gene transfer and recombination are
responsible for the P-nga-ifs-slo variation in these genotypes rather than extensive
genome-wide divergence or emm “switching.”
Variants of the nga-ifs-slo promoter associated with altered expression. Re-
combination of P-nga-ifs-slo and surrounding regions in emm1 and emm89 conferred
higher activity and expression of NGA (NADase) and SLO (1, 3, 10). This change in
expression was linked to the combination of three key residues at 27, 22, and 18
within the nga-ifs-slo promoter. A27G22T18 at these key sites was associated with
high nga-ifs-slo promoter activity in emm1 and emergent emm89 following recom-
bination (also referred to as Pnga3) compared to low promoter activity of historical
emm1 and emm89, associated with the key site combinations A27T22C18 and
G27T22T18, respectively (2) (Fig. 3A). We compared the67-bp nga-ifs-slo promoter
region of the 344 BSAC collection isolate genomes to identify different variants. We
expanded the data analyzed by including assembled genome data from 5,000
isolates representing 54 different emm types: from Cambridge University Hospital (CUH)
(11), from England and Wales collected by Public Health England (PHE) in 2014 and
2015 (PHE-2014/15) (12, 13), and from the United States collected by the Active
Bacterial Core Surveillance System (ABCs) in 2015 (ABCs-2015) (14). We excluded 39
emm types represented by fewer than 3 isolates (Data Set S2).
FIG 3 Variants of the nga-ifs-slo promoter. (A) The three key residues predicted to inﬂuence promoter activity are highlighted in blue,
with those associated with high activity in red font. We identiﬁed four combinations of these residues (four promoter types) with subtype
variants differing in residues other than 27, 22, and 18 (residue positions relative to the underlined 35 and 10 regions) in the
predicted 67-bp promoter region (9). The combination of A27T22C18 subtype 1.1 in historical emm1 and G27T22T18 subtype 2.1 in
older emm89 isolates has been shown to be associated with low-level promoter activity. A27G22T18 subtype 3.1 promoter in modern
emm1 and emergent variant emm89 has been shown to have high activity. A27T22T18 subtype 4 promoter has also been shown to
have high activity in emm28 (15). Subtypes 1.2, 1.3, and 2.3 were restricted to emm9, emm88, and emm32 strains, respectively. (B)
WebLogo representation of the variability in the 67-bp promoter region of nga-ifs-slo within the 54 different emm types. Key residues27,
22, and 18 are highlighted (star) and their positions are relative to the 35 and 10 boxes. Figure generated using WebLogo
(http://weblogo.berkeley.edu).
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Four combinations of the 27, 22, and 18 residues were found across all 5,271
isolates (Table 1); variant 1 A27T22C18 and variant 2 G27T22T18 are associated
with low promoter activity, while variant 3 A27G22T18 and variant 4 A27T22T18
are associated with high promoter activity. We also identiﬁed subtypes of the 67-bp
promoter region which varied at bases other than 27, 22, and 18 (Fig. 3A and B;
Table 1). A27T22C18 variant subtype 1.1 and G27T22T18 variant subtype 2.1 were
both previously conﬁrmed to have low promoter activity (2) and were the most
common variants found across genotypes. Other subtypes of these variants were
restricted to single genotypes except G27T22T18 variant subtype 2.2, which differed
by a single substitution of C for a T residue at40 bp. Two subtypes of the high-activity
variant A27G22T18 were found, the most common being subtype 3.1, associated
with emm1 and emergent emm89, and subtype 3.2, which was found predominantly in
the genomes of emm4 and emm87 and differed from subtype 3.1 by a single substi-
tution of G for T at 40 bp. We measured the activity of NADase in the culture
supernatants of strains representing different promoter subtypes and found that the
presence of T/G/C at 40 bp did not affect activity of the promoter (see Fig. S2). The
fourth promoter variant, A27T22T18, is also associated with high activity (15) and was
identiﬁed in the genomes of emm28, emm75, and all emm78 isolates. Only three emm types
were exclusively associated with the high-activity promoter variant A27G22T18: emm1,
emm3, and emm12. Other emm types with the high-activity promoter variant also had one
or more of the other three promoter variants, suggesting a mixed population or, as in
the case of emm89, an evolving population.
We sought evidence for acquisition of the high-activity-associated promoter
A27G22T18 variant by emm genotypes where the dominant or ancestral state was
a low-activity-associated promoter; these included (in addition to the aforementioned
emm89) emm75, emm76, emm77, emm81, emm82, emm87, emm94, and emm108, all of
which are emm types frequently identiﬁed in the United Kingdom and the United
States (12–14). Although one emm28 was found to carry the high-activity-associated
A27G22T18 promoter, the rest of the emm28 population was divided between either
A27T22C18 or A27T22T18 variants. The data pointed to a switch in P-nga-ifs-slo
in all cases rather than an emm switch, except for emm82, where the emm82 gene
replaced the emm12 gene in an emm12 genetic background (14).
High level of mutations within the capsule locus leading to truncations of HasA
or HasB. As well as recombination around the P-nga-ifs-slo region, the emergent ST101
TABLE 1 Three key residue variants within the nga-ifs-slo promoter
Promoter variant Type Genotype (% of isolates)a
A27T22C18 1.1 4 (1), 8 (100), 9 (92), 11 (100), 22 (3), 25 (33), 28 (87.7),
33 (100), 41 (100), 43 (100), 44 (9), 49 (100), 53 (100),
58 (15), 60 (100), 63 (100), 75 (9), 76 (41), 77 (29), 81
(23), 82 (1), 88 (33), 89 (1), 90 (4), 92 (100), 94 (6),
101 (100), 102 (50), 103 (17), 106 (100), 108 (89), 110
(100), 113 (100), 151 (100), 168 (100), 232 (100)
1.2 9 (8)
1.3 88 (67)
G27T22T18 2.1 5 (100), 6 (100), 18 (100), 25 (67), 44 (28), 68 (100), 75
(1), 76 (5), 77 (1), 82 (1), 87 (2), 89 (6), 90 (96), 91
(100), 102 (50), 103 (83), 104 (100), 118 (100)
2.2 2 (100), 27 (100), 44 (62), 58 (85), 59 (100), 73 (100), 76
(11), 77 (36), 82 (89), 83 (100)
2.3 32 (100)
A27G22T18 3.1 1 (100), 3 (100), 12 (100), 22 (97), 75 (90), 76 (43), 81
(77), 82 (9), 89 (93), 94 (94), 108 (11)
3.2 4 (99), 28 (0.3), 77 (34), 87 (98)
A27T22T18 4 28 (12), 78 (100)
aBoldface font indicates genotypes with more than one variant within the population.
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variant of emm89 had also undergone recombination surrounding the hasABC locus,
and, in place of the hasABC genes, there was a region of 156 bp that was not found in
genotypes with the capsule locus but is found in the acapsular emm4 and emm22
isolates (3). To identify any similar events in other genotypes, we examined the sequences
of hasA, hasB, and hasC in the assemblies of isolates from the BSAC collection as well
as CUH (11), PHE-2014/15 (12, 13), and ABCs-2015 (14) collections for gene presence as
well as premature stop codon mutations (Fig. 4). The hasABC locus was absent in the
majority of emm89 isolates, consistent with the previous observations describing the
recent emergence of the acapsular emm89 variant (3). Similarly, the hasABC genes were
absent in all emm4 and emm22 isolates, as previously identiﬁed (16), except for two
emm4 isolates and one emm22 isolate which had an intact hasABC locus predicted to
encode full-length proteins. We conﬁrmed the genotypes of these isolates by emm
typing the assembled genomes. Multilocus sequence typing (MLST) and phylogenetic
analysis indicated that they both had a very different genetic background to other
FIG 4 Nonfunctional mutations within the capsule locus genes. The hasABC genes were extracted from the assembled genomes of
BSAC, CUH, PHE-2015/15, and ABCs-2015 isolate genome collections, and polymorphisms or indels leading to nonsense mutations and
premature stop codons, as well as gene absence, were identiﬁed. The percentage of isolates with full-length (gray), truncated (red),
or absent (black) HasA, HasB, or HasC is depicted for each of the 54 emm types. emm types with fewer than 3 isolates were excluded.
N 5,271 isolates genomes shown. Mutations in HasA were detected in more than 50% of isolates belonging to genotypes emm8
(n 3/4), emm11 (n 63/108), emm25 (n 2/3), emm27 (n 3/3), emm28 (n 358/363), emm58 (n 21/33), emm68 (n 12/14),
emm73 (n 25/27), emm77 (n 72/80), emm78 (n 8/8), emm87 (n 119/121), and emm102 (n 6/6). Mutations in HasB were
detected in 100% of emm94 isolates (n 54/54) and 60% to 77% of emm63 (n 3/5), emm81 (n 50/65), and emm90 (n 16/26)
isolates.
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emm4 or emm22 populations, suggesting that these were not typical of these emm
types; therefore, they represent examples of emm switching. Interestingly, we also
identiﬁed a similar replacement of hasABC for the 156-bp region in one emm28 isolate
(PHE-2014/15, GASEMM1261 [13]), but phylogenetic analysis suggested this was highly
divergent from the rest of the emm28 population, likely to represent another example
of emm switching. Isolated examples of individual hasA or hasB gene loss were
identiﬁed in the genomes of isolates belonging to emm1 (n 1), emm3 (n 1), emm11
(n 1), emm12 (n 4), and emm108 (n 2).
The majority of genotypes (35/54 [65%]) had isolates without genes or truncation
mutations in at least one of the hasABC genes (Fig. 4). Mutations in hasC were rare and
only detected in one isolate, an emm77 isolate, which also had a mutation within hasA.
Within seven of the eight emm types for which we identiﬁed potential P-nga-ifs-slo
recombination, a high percentage of isolates had inactivating mutations in hasA and
hasB, suggesting a possible association between an acapsular genotype/phenotype
and recombination of P-nga-ifs-slo to gain a high-activity promoter. Including the
previously identiﬁed emm1 and emm89 recombination events, P-nga-ifs-slo recombi-
nation to gain a high-activity promoter was detected in 10 genotypes, and in all 10 of
these genotypes (100%) were isolates with hasAB gene mutations or gene absence.
However, in the 44 genotypes that had not undergone P-nga-ifs-slo recombination to
gain a high-activity promoter, signiﬁcantly fewer (25/44 [57%]) had isolates with a
hasAB gene mutation or gene absence (21df  6.662, P  0.0098).
Recombination of P-nga-ifs-slo and surrounding regions. To conﬁrm our predic-
tion that genotypes emm28, emm75, emm76, emm77, emm81, emm87, emm94, and
emm108 had undergone recombination around P-nga-ifs-slo, we mapped all the ge-
nome sequence data for each genotype to the emm89 reference genome H293.
Gubbins analysis of SNP clustering predicted regions of recombination spanning the
nga-ifs-slo region and varied in length in all eight genotypes (Fig. 5). To further analyze
the recombination of these genotypes and potential capsule loss, we studied the
population structure of each genotype individually.
Recombination within emm28 and emm87 around P-nga-ifs-slo and the capsule
locus. The genotypes emm28 and emm87 were the sixth and ﬁfth most common in the
BSAC collection, respectively, and emm28 was previously noted to be a major cause of
infection in high-income countries (17). We focused attention on emm28 and emm87,
as there has been little genomic work on these genotypes so far.
All BSAC emm28 isolates carried the A27T22C18 low-activity-associated pro-
moter, but inclusion of international genomic data identiﬁed A27T22T18 variant-
carrying isolates. These two promoter variants were associated with different major
FIG 5 Regions of recombination spanning the P-nga-ifs-slo locus. Recombination across the nga, ifs, and slo genes (blue arrows) was
identiﬁed in eight genotypes in addition to the previously described emm1 and emm89. Length of recombination, predicted by SNP
cluster analysis, ranged from 6 kb to 36 kb. With the exception of emm75, all regions also encompassed the promoter of nga-ifs-slo. All
regions are shown relative to an 40-kb region within the reference genome H293, and genes within this region are depicted as arrows.
Recombination in emm1 extended beyond that depicted here and is shown as a broken line.
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lineages within the entire population of 379 international emm28 isolates, including
one newly sequenced English isolate originally isolated in 1938. The majority of isolates
(n 373) clustered either with the reference MGAS6180 strain (United States) (18) or
with the reference MEW123 strain (United States) (19) (Fig. 6A). Gubbins analysis for
core SNP clustering predicted that the two lineages were distinguished by a single
28,200-bp region of recombination, between positions 142,426 bp (ntpE; M28_
Spy0126) and 170,625 bp (M28_Spy0153) of the MGAS6180 chromosome. This
suggests the emergence of one lineage from the other through a single recombination
event followed by expansion of both lineages (Fig. 6B). Within the recombination
region was the P-nga-ifs-slo locus, which differed between the two lineages; although
unique in the MGAS6180-like lineage and with low-activity-associated promoter resi-
dues A27T22C18, the MEW123-like lineage had a P-nga-ifs-slo identical to that found
in emm78 isolates, with the three key residues of A27T22T18. This is supported by
recent ﬁndings identifying two main lineages within emm28 and that the A27T22T18
promoter variant conferred greater toxin expression than A27T22C18 (15).
Although we identiﬁed an A27G22T18 high-activity variant of P-nga-ifs-slo within
emm28, this was only associated with the highly divergent GASEMM1261 isolate that
may represent an emm switching event. This isolate, along with three other PHE-
2014/15 isolates (GASEMM2648, GASEMM1396, and GASEMM1353), also representing
highly divergent lineages, were excluded from the phylogenetic analysis.
All emm28 isolates, regardless of lineage and including MGAS6180 (originally iso-
lated in the 1990s), had the same insertion mutation within hasA of an A residue after
219 bp. This insertion was predicted to lead to a frameshift and a premature stop codon
after 72 amino acids (aa) instead of full-length 420 aa, rendering hasA a pseudogene.
FIG 6 Recombination within the emm28 and emm87 populations. (A) Maximum likelihood phylogeny constructed with 33,537 core SNPs
following mapping of all available emm28 genome data to the emm28 MGAS6180 reference genome (white square) (18). Modern UK
isolates (red circles): BSAC (n 15), CUH (n 13 [11]), and PHE-2014/15 (n 240 [12, 13]); one historical English isolate from 1938 (brown
square). North American isolates (blue circles): ABCs-2015 (n 95 [14]), Canada (2011 to 2013, n 4 [47]), and completed genome strain
HarveyGAS (United States, 2017 [48]). Other isolates: Lebanon (n 1, orange circle [49]), Australia (n 5, green circles [50]), and France
(STAB10015 [51], M28PF1 [52], turquoise circles). Total number of isolate genomes was 379. Two lineages of emm28 were identiﬁed, one
clustering with MGAS6180 (white square) and the other (shaded gray) clustering with MEW123 (2012 USA [19], white circle). (B) Regions
of recombination were then identiﬁed within the emm28 genome alignment and removed before reconstructing a phylogenetic tree
using 17,885 variable sites. (C) Maximum likelihood phylogeny constructed with 6,292 core SNPs following mapping of all available emm87
genome sequence data to the reference emm87 strain NGAS743 (Canada, white circle [53]). UK isolates (red circles): BSAC (2001 to 2011,
n 22), CUH (2008, n 1 [11]), and PHE-2014/15 (n 72, [12, 13]). North American isolates (blue circles): ABCs-2015 (n 26 [14]), Canada
(n 23 [47, 53]), and Texas Children’s Hospital (2012 to 2016, n 27 [54]). NCTC12065 (GenBank accession number GCA_900460075.1)
isolate from1970 to 1980 was also included (brown square). Total number of isolates was 173. Three isolates (shaded gray) were distinct
from the main population. The branch was shortened for one isolate for presentation purposes. (D) Regions of recombination were
identiﬁed within the emm87 genome alignment and removed before reconstructing a phylogenetic tree using 1,531 variable sites. Isolates
indicated by an asterisk (*) in both emm28 and emm87 populations were predicted to have undergone recombination in regions
surrounding the hasABC locus. Scale bars represent single nucleotide polymorphisms. PHE-2014/15 emm28 isolates GASEMM1261,
GASEMM2648, GASEMM1396, and GASEMM1353 were removed for presentation purposes, as they represented highly divergent lineages.
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Some isolates also had additional mutations in hasA: a deletion of an A residue in a
septa-A tract leading to a frameshift and a stop codon after 7 aa (n 1); a deletion of
a T residue in a septa-T tract leading to a frameshift and a stop codon after 15 aa
(n 2); an insertion of an A residue after 57 bp leading to a frameshift and a stop codon
after 46 aa (n 3). The loss of full-length HasA would render the isolates acapsular.
In emm28, there were just two exceptions where hasA was found to be intact:
the historical emm28 isolate from 1938 had an intact hasABC capsule operon, and
BSAC_bs2099, which appeared to have undergone recombination to acquire a
22,316-bp region surrounding the hasABC genes that was 99% identical to the same
region in emm2 isolate MGAS10270, suggesting emm2 might be the donor for this
recombination. Both isolates were predicted to express full-length HasA and synthesize
capsule. Taken together, in comparison with the oldest emm28 isolate, the data showed
that post-1930s emm28 isolates became acapsular through mutation, but the contem-
porary population is divided into two major lineages, MEW123-like and MGAS6180-like
lineages, that may differ in nga-ifs-slo expression. Additionally, there was evidence of
geographical structure in the population: the MEW123-like lineage comprised mainly of
North American isolates (39/44) and only ﬁve from England/Wales; isolates from
Australia, France, and Lebanon were MGAS6180-like, along with the rest of the Eng-
land/Wales isolates.
Phylogenetic analysis of the BSAC emm87 population was expanded and compared
with publicly available emm87 genome sequence data, totaling 173 isolate genomes
from the United Kingdom and North America, including one historical NCTC UK isolate
from 1970 to 1980 (NCTC12065, GenBank accession number GCA_900460075.1).
Gubbins analysis predicted a single 20,506-bp region of recombination surrounding the
P-nga-ifs-slo region that distinguished the main population from the oldest BSAC
isolates from 2001 and the historical 1970 to 1980 NCTC isolate (Fig. 6C). While the two
2001 BSAC isolates and the NCTC isolate had a P-nga-ifs-slo variant with low-activity-
associated promoter residues, G27T22T18, all other emm87 isolates had a P-nga-ifs-slo
region with high-activity-associated promoter residues, A27G22T18, identical to that
found in emm4 and some emm77 isolates. This suggested the emergence of a new
lineage through a single recombination event followed by expansion within the
population, redolent of that previously observed in emm89 (Fig. 6D).
Similar to emm28, all emm87 isolates, bar four, had an insertion of an A residue after
57 bp that resulted in a frameshift mutation in hasA and the introduction of a prema-
ture stop codon after 46 aa of HasA. This mutation was also identiﬁed within the
historical NCTC isolate but was not found in the two 2001 BSAC isolates that had an
intact hasABC locus. This mutation was also absent in two PHE-2014/15 isolates that
had undergone an additional recombination event (32,243 bp) surrounding the hasABC
locus; although, as this region shared 100% DNA identity to emm28 isolate MGAS6180,
HasA is truncated. Overall the data showed that, like emm89 isolates, contemporary
emm87 isolates are acapsular with a high-activity nga-ifs-slo promoter, suggesting that this
emm lineage may have recently shifted toward this genotype/phenotype.
Recombination within different multilocus sequence types of emm75. The emm75
genotype is of interest as a common cause of noninvasive infection in the United
Kingdom; it is also used in models of nasopharyngeal infection (20, 21). Eleven emm75
isolates were present in the BSAC collection, all multilocus sequence type (ST) 150.
When we incorporated other available genome sequence data for emm75 (n 174),
including two newly sequenced historical English emm75 isolates from 1937 and 1938,
two major lineages were identiﬁed, characterized by two different MLSTs: ST49 or
ST150 (Fig. 7A). Although the two historic English isolates were ST49, like the majority
of modern North American isolates, the modern England/Wales isolates were predom-
inantly ST150.
Although these two ST lineages differed in the P-nga-ifs-slo region, there was a high
level of predicted recombination across the genomes of both STs, perhaps indicative of
historic emm switching or extensive genetic exchange. ST49 isolates had the
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subtype 1.1 low-activity A27T22C18 promoter, whereas all ST150 isolates had the
A27G22T18 subtype 3.1 high-activity promoter variant, identical to that of emm1
and emm89. Modern ST49 isolates did, however, differ from historic 1930s isolates by
ten distinct regions of predicted recombination (Fig. 7B), including a region spanning
the nga-ifs-slo locus, although this did not include the promoter region. We did not
detect any mutations affecting the capsule region in emm75. Taken together, emm75
was characterized by two major MLST lineages differing in P-nga-ifs-slo promoter
activity genotypes but without evidence of recent recombination or loss of capsule.
Lineages associated with recombination in emm76, emm77, and emm81. The
phylogeny of all available genome data for emm76, emm77, and emm81 conﬁrmed the
presence of diverse lineages associated with different MLSTs (Fig. 8A to C). In all
genotypes, however, there was a dominant MLST lineage representing the majority of
isolates: ST50 emm76, ST63 emm77, and ST624 emm81. Within the dominant MLST
lineages of emm76 and emm77, there were sublineages that were associated with
different P-nga-ifs-slo variants as well as loss of functional HasA through mutation.
We identiﬁed ﬁve different MLSTs within emm76 (Fig. 8A), but the majority of
isolates (30/38) belonged to ST50, including both BSAC isolates. Recombination analysis
of the ST50 lineage identiﬁed a sublineage that differed from other ST50 isolates by 19
regions of recombination (see Fig. S3). One of these regions encompassed P-nga-ifs-slo,
conferring a P-nga-ifs-slo variant closely related to that of modern emm1 and emm89
with an identical high-activity promoter (subtype 3.1). This sublineage was dominated
by PHE-2014/15 isolates and also contained the more recent of the two BSAC isolates
(2008). All isolates in this sublineage, except one, also had a nonsense mutation within
hasA of a C-to-T change at 646 bp, resulting in a premature stop codon after 215 aa,
likely to render the isolates acapsular. Only one ST50 isolate outside this sublineage had
the same hasA C646T change. All other emm76 isolates would express full-length HasA.
FIG 7 Two lineages within emm75. (A) Maximum likelihood phylogeny constructed with 9,241 core SNPs following
mapping of all available emm75 genome sequence data to the genome of French strain STAB090229 (white circle)
(55). Modern UK collections (red circles): BSAC (n 11), CUH (n 6 [11]), and PHE-2014/15 (n 141 [12, 13]; two
English historical isolates (brown squares) from 1937 and 1938. North American isolates (blue circles): ABCs-2015
(n 20 [14]), NGAS344, and NGAS604 from Canada 2011 to 2012 (53). French strains (turquoise circles):
STAB120304 (2012) and STAB14018 (2014) (55). Total number of isolates was 185. Two lineages were identiﬁed,
generally characterized by the MLSTs: ST49 (shaded gray) or ST150 (with minor MSLT variants ST788, ST851, and
ST861 within these lineages). (B) Gubbins analysis identiﬁed ten regions of predicted recombination (red lines) in
all modern ST49 compared to historical 1930s ST49 across the genome (indicated across the top). One region
included P-nga-ifs-slo (shaded gray). The phylogenetic tree was constructed with 1,953 variable sites following
removal of predicted regions of recombination. Scale bars represent single nucleotide polymorphisms. One
PHE-2014/15 isolate (GASEMM1722) was excluded for presentation purposes, as it was highly divergent from the
rest of the population.
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FIG 8 Variants of P-nga-ifs-slo and capsule mutations associated with lineages of emm76, emm77, and emm81. Maximum likelihood
phylogeny identiﬁed multiple sequence type (ST) lineages within the populations of emm76 (A), emm77 (B), and emm81 (C). Collection
indicates either BSAC or CUH (dark red), PHE-2014/15 isolates (red), ABCs-2015 (blue), or English historical (brown). Dates for BSAC,
CUH, or historical are shown; other isolates were from 2014/2015. STs are indicated on the right and major lineages are shaded gray.
(A) Genome data for emm76 was mapped to the de novo assembled sequence of BSAC_bs448 from 2002, selected as the oldest isolate
(Continued on next page)
Turner et al. ®
November/December 2019 Volume 10 Issue 6 e02521-19 mbio.asm.org 12
Two sublineages were also identiﬁed within the dominant emm77 lineage ST63
(Fig. 8B), and one was associated with the high-activity cluster P-nga-ifs-slo variant
compared to predicted low-activity variants found in the other emm77 lineages. Recom-
bination analysis predicted only two regions of recombination distinguishing the two
sublineages: a region of 17,954 bp surrounding P-nga-ifs-slo, and a 173-bp region
within a hypothetical gene (SPYH293_00394) (see Fig. S4). While all BSAC emm77
isolates (years 2001 to 2009) were ST63 with low-activity P-nga-ifs-slo, PHE isolates from
2014 to 2015 were almost evenly divided between the two sublineages, indicating a
potential recent change in England/Wales. All ST63 isolates except two had a deletion
of a T residue within a septa-poly(T) tract at 458 bp in hasA, predicted to truncate the
HasA protein after 154 aa. The two exceptions were predicted to encode full-length
HasA and were associated with low-activity P-nga-ifs-slo promoter variants. Although
also not associated with high-activity P-nga-ifs-slo promoter variants, other lineages of
emm77 also carried mutations within hasA that would truncate HasA; ST399 isolates
carried an insertion of a T residue at 71 bp of the hasA gene resulting in a premature
stop codon after 46 aa, and two ST133 isolates carried a G894A substitution resulting
in a premature stop codon after amino acid residue 297.
The emm81 population (n 68) was more diverse with nine different sequence
types (Fig. 8C), but the majority of isolates (41/68) were ST624 or the single locus variant
ST837 (9/68; one SNP in recP allele) within the same lineage. ST171 was restricted to
three historical isolates originally collected in 1938 and 1939. We did not detect any
hasABC variations that would disrupt translation in emm81 lineages except for the
dominant group of ST624/ST837, where we identiﬁed an A residue insertion at 128 bp
in hasB resulting in a frameshift and premature stop codon after 50 aa. All ST624/ST837
isolates carried the high-activity cluster P-nga-ifs-slo variant identical to that seen in
emm3 compared to all other lineages associated with other low-activity P-nga-ifs-slo
variants. Recombination analysis identiﬁed extensive recombination had occurred
within emm81 leading to the different levels of diversity, but we identiﬁed one region
of recombination that distinguished the ST624/ST837 lineage from the closely related
ST909 and ST117 populations (see Fig. S5). This region surrounded the P-nga-ifs-slo
locus, suggesting ST624/ST837 gained the high-activity cluster P-nga-ifs-slo variant
through recombination, like other emm types, potentially from emm3. The emergence
of the high-activity P-nga-ifs-slo variant and truncated HasB ST624/ST837 lineage may
be recent in England/Wales, as all BSAC isolates obtained prior to 2009 were outside
this lineage.
High-activity cluster P-nga-ifs-slo variants gained by recombination in emm94
and emm108. Within emm94, we identiﬁed a P-nga-ifs-slo identical to that found in
emm1 with high-activity promoter variant subtype 3.1. Phylogenetic analysis of 51
emm94 isolates identiﬁed a dominant lineage among England/Wales isolates separate
to the single US isolate and two England/Wales isolates (see Fig. S6A) that belonged to
FIG 8 Legend (Continued)
representing the genotype. Genome data from a total of 38 isolates were used: BSAC (n 2), PHE-2014/15 (n 18 [12, 13]), ABCs-2015
(n 18 [14]). Predicted prophage regions were removed and a maximum likelihood phylogenetic tree constructed from 30,264 core
SNPs. Five STs were identiﬁed (indicated on right of tree), but the main lineage was ST50. (B) All emm77 genome data were mapped
to the de novo assembled sequence of BSAC_bs150 from 2001. Genome data from a total of 80 isolates were used: BSAC (n 5),
PHE-2014/15 (n 21 [12, 13]), and ABCs-2015 (n 54 [14]). Four STs were identiﬁed but the main lineage was ST63, with one isolate
in this lineage being single locus variant ST1125. Predicted prophage regions were removed, and a maximum likelihood phylogenetic
tree was constructed from 34,760 core SNPs. (C) All emm81 genome data were mapped to the de novo assembled seqeunce of
BSAC_bs229 from 2001. Genome data from a total of 68 isolates were used: BSAC (n 9), CUH (n 1 [11]), PHE-2014/15 (n 29 [12,
13]), ABCs-2015 (n 26 [14]), and English historical 1930s (n 3). Predicted prophage regions were removed, and a maximum
likelihood phylogenetic tree was constructed from 42,258 core SNPs. Nine STs were identiﬁed but the main lineage was ST624 with
and minor (single base change in recP) ST variant ST837. We identiﬁed variants of P-nga-ifs-slo (P) associated with one of three
combinations of key promoter residues, including the high-activity-associated A27G22T18 (P; black). For emm76 (A) and emm77 (B),
mutations were detected in hasA predicted to truncate HasA (H; black). (C) All emm81 isolates were predicted to express full-length
HasA, but the ST624/ST837 lineage carried a mutation within hasB leading to a truncated HasB (H; gray). Branches are colored based
on bootstrap support (scale bar provided). Scale bars represent substitutions per site. Isolates used as references for mapping indicated
with black circles. Branches for lineages outside main lineages were shortened for presentation purposes (indicated by line breaks).
C; collection, P; promoter key residue combination, H; full-length or truncated HasA or HasB.
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ST89. Gubbins analysis predicted 11 regions of recombination in all lineage-associated
isolates compared to the three outlying isolates, including one (22,648 bp) that
encompassed P-nga-ifs-slo, transferring a high-activity A27G22T18 P-nga-ifs-slo vari-
ant. All emm94 isolates contained an indel within hasB compared to the reference
(H293), losing 6 bp and gaining 13 bp between 127 and 133 bp. This variation causes
a frameshift and would truncate the HasB protein after 45 aa.
We identiﬁed a similar high-activity cluster P-nga-ifs-slo variant within a single emm108
genome originating from the United States. Within the 9 isolates from PHE-2014/15 (n 7)
and ABCs-2015 (n 2), there were two sequence types, ST1088 and ST14. ST14 was
represented by the only two ABCs-2015 isolates, and we identiﬁed that both had lost
the entire hasB gene, although hasA and hasC were still present (Fig. S6B). Additionally,
one of the ABCs-2015 isolates had undergone recombination of a single 29,683-bp
region surrounding the P-nga-ifs-slo, replacing P-nga-ifs-slo for one identical to that
found in emm3 with high-activity promoter variant A27G22T18 subtype 3.1.
Mobile genetic elements and antimicrobial resistance. The acquisition of mobile
genetic elements such as prophages and transposons may also be inﬂuenced by
capsule expression and can also inﬂuence the expansion and success of new lineages.
We therefore determined the presence of prophage-associated superantigen and
DNase genes as well as antimicrobial resistance genes to estimate the number of
mobile genetic elements present within each isolate of the genotypes emm28, emm75,
-76, -77, -81, -87, -94, and -108 (Fig. S3 to S5; Data Set S3). On average, there were 4.4
elements present in isolates predicted to express full-length HasABC compared to 2.5
elements present in isolates with hasABC gene mutations or gene absence, suggesting
that the presence of capsule does not hinder mobile genetic elements. We also
detected no link between lineages within these genotypes that had undergone P-nga-
ifs-slo recombination and mobile factors, except within emm76 and emm77. Isolates
belonging to the emm76 ST50 sublineage associated with HasA mutation and P-nga-
ifs-slo recombination all carried the prophage-associate superantigen genes speH and
speI as well as a diverse variant of the DNase spd3 and the erythromycin resistance gene
ermB (Fig. S3). This differed from the other ST50 isolates that carried another variant of
spd3 and multiple different resistance genes. The sublineage of ST63 emm77 associated
with P-nga-ifs-slo recombination also carried spd3, and all, except one isolate, carried
the erythromycin resistance gene ermTR; both genes were not common in other ST63
emm77 isolates (Fig. S4).
DISCUSSION
The emergence of new internationally successful lineages of S. pyogenes can be
driven by recombination-related genome remodeling, as demonstrated by emm1 and
emm89. The transfer of a P-nga-ifs-slo region conferring increased expression to the
new variant was common to both genotypes. In the case of emm89, ﬁve other regions
of recombination were identiﬁed in the emergent variant, one resulting in the loss of
the hyaluronic acid capsule. Although, potentially, all six regions of recombination
combined underpinned the success of the emergent emm89, we have shown here that
recombination of P-nga-ifs-slo has occurred in other leading emm types as well as a
high frequency of capsule loss through mutation. These data point to an association
between genetic change affecting capsule and recombination affecting the P-nga-ifs-
slo locus, conferring increased production of nga-ifs-slo; in some cases (notably emm87,
emm89, and emm94), this has further been associated with an apparent ﬁtness advan-
tage and expansion within the population.
A number of genotypes were found to be associated with multiple variants of
P-nga-ifs-slo. The majority of genotypes had P-nga-ifs-slo variants with the low-activity-
promoter associated with three key residue variants: G27T22T18 or A27T22C18.
Only emm1, emm3, and emm12 were exclusively associated with the high-activity
A27G22T18 variant. We have shown that the same high-activity promoter variant is
present in isolates belonging to twelve other emm types, notably, emm76, emm77,
emm81, emm87, and emm94, although this is not a consistent feature in these geno-
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types due to emm switching or recombination. We identiﬁed four combinations of the
three key promoter residues and several subtypes of the 67-bp promoter that varied in
bases other than those at the 27, 22, and 18 key positions. Although some
subtypes were restricted to single genotypes, variation in the 40 base led to the
subtype 2.2 of G27T22T18 and subtype 3.2 of A27G22T18. We measured the
activity of NADase in representative strains and genotypes of these promoter variants
and found that variation in the 40 base did not impact the activity conferred by the
27, 22, and 18 bases. Although we predicted the level of nga and slo expression
based on the promoter variant, this may not relate to actual expression given the level
of other genetic variation between genotypes. However, our consistent ﬁndings of
lineages emerging following acquisition of the high-activity promoter variant supports
the hypothesis that this confers some beneﬁt that may relate to increased toxin
expression.
Intriguingly, where we identiﬁed an acquisition of the high-activity promoter variant
through recombination, these genotypes also had a genetic change in the capsule
locus, likely rendering the organism unable to make capsule (hasA mutation) or only
low levels of capsule (hasB mutation). To date, only emm4, emm22, and the emergent
emm89 lineages are known to lack all three genes required to synthesize capsule. Here,
we identiﬁed mutations that would truncate HasA and HasB in 35% of all isolates and
65% (35/54) of all genotypes. As the majority of isolates included in this study were
invasive or sterile-site isolates, the ﬁndings further challenge the dogma that the
hyaluronan capsule is required for full virulence of S. pyogenes and, in addition, lend
credence to the possibility that the increased expression of NADase and SLO may in
some way compensate for the lack of capsule (22). While capsule has been shown to
underpin resistance to opsonophagocytic killing in the most constitutively hyperen-
capsulated genotypes such as emm18 (23, 24), there is less evidence that it contributes
measurably to opsonophagocytosis killing resistance in other genotypes (3). Whether
the loss of capsule synthesis is of beneﬁt to S. pyogenes is uncertain; the capsule may
shield several key adhesins used for interaction with host epithelium and fomites but
may also act as a barrier to transformation with DNA. An accumulation of hasABC
inactivating mutations has been identiﬁed during long-term carriage (25); although for
some genotypes, capsule loss reduced survival in whole human blood, a high number
of acapsular hasA mutants have also recently been found to be causing a high level of
disease in children, including emm1, emm3, and emm12 (26).
The process of recombination in S. pyogenes is not well understood, and natural
competence has only been demonstrated once and under conditions of bioﬁlm or
nasopharyngeal infection (27). We do not know if the six regions of recombination that
led to the emergence of the new ST101 emm89 variant occurred simultaneously,
although no intermediate isolates have been identiﬁed. The loss of the hyaluronic acid
capsule in the new emergent emm89, along with our consistent ﬁndings of inactivating
mutations associated with P-nga-ifs-slo transfer, indicates either (i) the process of
recombination requires the inactivation of capsule, (ii) capsule-negative S. pyogenes
requires high expression of nga-ifs-slo for survival, or (iii) that a capsule-negative
phenotype combined with high expression of nga-ifs-slo provides a greater selective
advantage to S. pyogenes.
The phylogeny of emm28, emm87, emm77, emm94, and emm108 indicated that
mutations in hasA or hasB occurred prior to recombination of P-nga-ifs-slo, supporting
the ﬁrst hypothesis that prior capsule inactivation is required for recombination. There
is no evidence, however, to suggest this was required for recombination in the emm1
population. It could be hypothesized that capsule acts as a barrier to genetic exchange,
but there has also been a positive genetic association of capsule to recombination rates
(28). A positive association may, however, be related only to species expressing
antigenic capsule, whereby recombination is required to introduce variation for im-
mune escape.
The hasC gene is not essential for capsule synthesis (29), because a paralog of hasC
exists within the S. pyogenes genome. A paralog for hasB (hasB.2) also exists elsewhere
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in the S. pyogenes chromosome and can act in the absence of hasB to produce low
levels of capsule (30), but hasA is absolutely essential for capsule synthesis (29). The
mutations in hasA in emm28 and emm87 have been previously noted and conﬁrmed to
render the isolates acapsular (26, 31). Not all acapsular isolates were found to carry the
high-activity promoter of nga-ifs-slo, despite being invasive, perhaps refuting the
hypothesis that the high-activity nga-ifs-slo promoter is essential for the survival of
acapsular S. pyogenes. High expression of nga-ifs-slo may also occur through other
mechanisms, for example, through mutation in regulatory systems. We looked at the
sequences of covRS and rocA, known to negatively regulate nga-ifs-slo, in all isolates
(see Data Set S2 in the supplemental material) and identiﬁed some emm-type speciﬁc
variants, consistent with our previous ﬁndings (11). We did not identify any other
genotypes where all isolates carried truncation mutations in rocA, such as emm3 and
emm18 that were previously conﬁrmed to affect function and increase expression of
rocA-covR-regulated virulence factors (23, 32), consistent with other ﬁndings (14). It is
unclear as to whether the amino acid changes in found in other genotypes would affect
function of rocA as well as covR and covS, and this requires further work.
Interestingly, we identiﬁed that the capsule locus is also a target for recombination
as, similarly to emm89, isolates within emm28 and emm87 had undergone recombina-
tion of this locus and surrounding regions, varying in length and restoring capsule
synthesis in emm28. Isolated examples of hasA or hasB gene loss were identiﬁed in
some genotypes, such as emm108, possibly due to internal recombination and deletion.
Only two emm4 isolates and one emm22 isolate were found to have P-nga-ifs-slo
variants that were not A27T22G18 high-activity promoter variants, and interestingly,
these isolates carried the hasABC genes, typically absent in emm4 and emm22. The high
genetic distance of these isolates to other emm4 and emm22 genomes indicated
potential emm switching of the emm4 or emm22 genes into different genetic back-
grounds. The single emm28 with a high-activity P-nga-ifs-slo variant may also be an
example of this, and was one of four emm28 isolates that did not cluster with the two
main emm28 lineages. Although we excluded them from our analysis, as we focused on
recombination within the two main lineages, the presence of highly diverse variants
within genotypes and the potential for emm-switching warrants further investigation,
particularly as the most promising current vaccine is multivalent toward common M
types (33).
All other genotypes carrying the high-activity P-nga-ifs-slo variant were found to
have undergone recombination of this region: emm28, emm75, emm76, emm77,
emm81, emm87, emm94, and emm108, as well as the previously described emm1 and
emm89.
Within emm87, we identiﬁed three isolates outside the main population lineage that
represented the oldest isolates in the collection: two from 2001 (different geographical
locations within England) and one NCTC strain from 1970 to 1980 (NCTC12065). A
single region of recombination surrounding the P-nga-ifs-slo locus distinguished the
main population lineage from the three older isolates, consistent with a recombination
event, but due to a lack of earlier isolates of emm87, we could not conﬁrm a
recombination-related shift in the population, as reported previously for emm89 and
emm1.
The existence of two lineages within the contemporary emm28 suggests that one
has not yet displaced the other, although the MEW123-like lineage was predominantly
US isolates, consistent with recent ﬁndings (15). The P-nga-ifs-slo region with the
high-activity-associated A27T22T18 and acquired through recombination by the
MEW123-like lineage was identical to that found in emm78, indicating emm78 as
the potential genetic donor. We found emm78 to have high levels of NADase activity,
as predicted, and interestingly, similarly to emm28, all eight emm78 isolates were
acapsular due to a deletion within the hasABC promoter region extending into hasA.
This again may support the hypothesis that capsule-negative S. pyogenes requires high
expression of nga-ifs-slo for survival.
A strength of this study was the systematic longitudinal sampling over a 10-year
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period; as expected, this again identiﬁed the shift in the emm89 population. Other emm
types exhibited lineages with different P-nga-ifs-slo variants, and those with the more
active promoter variant did appear to become dominant over time, similarly to emm1
and the emergent emm89 lineages. For example, the high-activity P-nga-ifs-slo ST63
lineage of emm77 was not detected in England/Wales isolates prior to 2014 and 2015.
Similarly, the high-activity P-nga-ifs-slo variant emm81 ST646/ST837 lineage was rep-
resented by only a single isolate (of six) collected between 2001 and 2009 but became
dominant by 2014 to 2015 in England/Wales and the United States. emm75 was the 6th
most common genotype in England/Wales in 2014 to 2015 and dominated by high-
activity P-nga-ifs-slo variant ST150 lineage yet was less common in the United States,
where ST49 with low-activity P-nga-ifs-slo is dominant. A high prevalence of emm94
was also found in England/Wales between 2014 and 2015 but was rare in the United
States (only 1 isolate). Our analysis of this genotype indicated there has been a
recombination-related change in the population, as we detected 11 regions of pre-
dicted recombination, including P-nga-ifs-slo, potentially conferring high toxin expres-
sion. The other ten regions of recombination may also provide advantages to this
lineage along with a potential low level of capsule through hasB mutation.
Other factors may also contribute to the success of emergent new lineages, includ-
ing mobile prophage-associated virulence factors and antimicrobial resistance genes.
Acquisition of mobile genetic elements did not appear to be affected by capsule loss;
indeed, fewer mobile genetic element-associated factors were detected in isolates with
capsule gene mutations than in isolates with functional capsule genes. A number of
bacteriophages that target S. pyogenes encode a hyaluronidase thought to allow the
bacteriophage to access the bacterial surface by degrading the outer capsule layer (34);
therefore, recombination of these elements is likely to be different from gene transfer
of core genetic regions, such as P-nga-ifs-slo.
We did, however, identify an association in the lineages of emm76 and emm77 with
prophage-associated virulence factors and antimicrobial resistance genes. It is possible
that the superantigens speH, speI, and DNase spd3 may also have contributed to the
success of the lineages that had undergone P-nga-ifs-slo recombination. Of concern is
that both emm76 and emm77 carried genes for resistance to tetracycline and erythro-
mycin, which were rarer in other genotypes. If the acapsular/high-toxin-expressing
lineages do expand in the population, it will be important to monitor the levels of
antimicrobial resistance in these lineages. This is also true for emm108, as tetM was
detected in all isolates, but the presence of antimicrobial resistance genes was rare in
emm28, emm75, emm81, emm87, and emm94, regardless of lineage.
The development and boosting of circulating antibodies to SLO is often used as a
diagnostic biomarker of recent S. pyogenes infection and is known to be more speciﬁc
to throat rather than skin infections. The genomic analysis provides explanation for this
historic and well-recognized association between anti-streptolysin O (ASO) titers and
disease patterns, due to known tissue tropism of S. pyogenes emm types. Whether the
alteration of SLO activity in different S. pyogenes strains might render such a test more
or less speciﬁc will be of interest, although it may explain observed differences in ASO
titers between genotypes (35). There is also the possibility that other beta hemolytic
streptococci might acquire similarly active SLO production, reducing the speciﬁcity of
ASO titer to S. pyogenes.
Our genomic analysis has uncovered convergent evolutionary pathways toward
capsule loss and recombination-related remodeling of the P-nga-ifs-slo locus in leading
contemporary genotypes. This suggests that a combination of capsule loss and gain of
high nga-ifs-slo expression provide a greater selective advantage than either of these
phenotypes alone. Acquisition of the high-activity promoter led to pandemic emm1
and emm89 clones that are dominant and highly successful. Active surveillance of the
lineages comprising emm76, emm77, emm81, emm87, emm94, and emm108 is required
to determine if capsule loss/reduction and recombination of P-nga-ifs-slo toward high
expression will trigger expansion toward additional pandemic clones in the next few
years.
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MATERIALS AND METHODS
Isolates. Three hundred forty-four isolates of S. pyogenes associated with bloodstream infections and
submitted to the British Society for Antimicrobial Chemotherapy (BSAC; http://www.bsacsurv.org) from
11 different sites across England between 2001 and 2011 were subjected to whole-genome sequencing
(see Data Set S1 in the supplemental material). All BSAC isolates were tested for antibiotic susceptibility
using the BSAC agar dilution method to determine MICs (36).
A further six isolates were sequenced from a historical collection of S. pyogenes originally collected
in the 1930s from puerperal sepsis patients at Queen Charlottes Hospital, London, UK; one emm28 isolate
from 1938 (ERR485803), two emm75 isolates from 1937 (ERR485807) and 1939 (ERR485820), and three
emm81 isolates from 1938 (ERR485805) and 1939 (ERR485801, ERR485802).
Genome sequencing. Streptococcal DNA was extracted using the QIAxtractor instrument according
to the manufacturer’s instructions (Qiagen, Hilden, Germany) or manually using a phenol-chloroform
method (37). DNA library preparation was conducted according to the Illumina protocol, and sequencing
was performed on an Illumina HiSeq 2000 with 100-cycle paired-end runs.
Genomes were de novo assembled using Velvet with the pipeline and improvements found at
https://github.com/sanger-pathogens/vr-codebase and https://github.com/sanger-pathogens/assembly
_improvement (38). Annotation was performed using Prokka. emm genotypes were determined from the
assemblies, and multilocus sequence types (MLSTs) were identiﬁed using the MLST database (https://
pubmlst.org/spyogenes/) and an in-house script (https://github.com/sanger-pathogens/mlst_check).
New MLSTs were submitted to the database (https://pubmlst.org/).
Genome sequence analysis. Sequence reads were mapped using SMALT (https://www.sanger.ac.uk/
science/tools/smalt-0) to the completed emm89 reference genome H293 (HG316453.2) (3), as this
genome contains no known prophage regions. Other reference genomes were also used where indicated
with predicted prophage regions (Table S1) excluded to obtain “core” SNPs. Maximum likelihood
phylogenetic trees were generated from aligned core SNPs using RAxML (39) with the GTR substitution
model and 100 bootstraps. Regions of recombination were predicted using Gubbins analysis with the
default parameters (40). Branches of phylogenetic trees were colored according to bootstrap support
using iTOL (41).
Other genome sequence data were obtained from the short read archive. We combined data collected
across England and Wales through Public Health England during 2014 and 2015 (PHE-2014/15) supplied by
Kapatai et al. (13) and Chalker et al. (12) from invasive and noninvasive S. pyogenes isolates. We also used data
supplied by Chochua et al. (14) collected by Active Bacterial Core Surveillance USA in 2015 (ABCs-2015) from
invasive S. pyogenes isolates. ABCs-2015 sequence data were preprocessed by Trimmomatic (42) to remove
adapters and low-quality sequences. PHE-2014/15 had already been preprocessed (12, 13). Genome data from
these collections were assembled de novo using Velvet (assembly statistics provided in Data Set S2), and any
isolates with greater than 2.2 Mbp total assembled length and/or more than 500 contig numbers were
excluded. We also used data from Turner et al. (11) of invasive and noninvasive isolates from the Cam-
bridgeshire region, UK, and collected through Cambridge University Hospital (CUH). We relied on the emm
types determined during the original studies and excluded any data where the emm type was uncertain or
negative. The genes hasA, hasB, hasC, covR, covS, and rocA, and the P-nga-ifs-slo were extracted from the
assembled genome using in silico PCR (https://github.com/simonrharris/in_silico_pcr). Capsule locus and
P-nga-ifs-slo variants were also conﬁrmed through manual inspection of mapping data where genotype
could not be accurately determined from the assembly.
Mapping of emm76, emm77, and emm81 sequence data was performed using de novo assembled
genome data from one BSAC collection isolate representing the equivalent genotype. Prophage regions
were predicted using PHASTER (43) and removed before SNP extraction.
Antimicrobial resistance genes were identiﬁed by srst2 (44) using the ARG-ANNOT database
(ARGannot_r2.fasta) (45). The presence of prophage-associated superantigen genes speA, speC, speH, speI,
speL, speM, and ssa was determined using srst2 and the feature database previously used by Chochua
et al. (14) available at https://github.com/BenJamesMetcalf. The presence of prophage-associated
DNAses genes sda, sdn, spd1, spd3, spd3v6, and spd4 was also determined using srst2 by adding regions
of these genes to the feature database. Representative alleles of these DNase genes were taken from
previous analysis (46) to identify regions that would detect all variants of each DNase, except we included
spd3v6 separate from spd3 as it represents a divergent allele to spd3. Sequences used are available at
Mendeley (https://data.mendeley.com/datasets/hzwjkj2gtp/1).
NADase activity. Activity of NADase was measured in culture supernatants as previously described
(3). Activity was determined as the highest dilution capable of hydrolyzing NAD. Isolates were selected
from the BSAC collection to represent different promoter variants for which there were three or more
isolates available that were lacking mutations in regulatory genes.
Data availability. Sequence data have been submitted to the European Nucleotide Archive (ENA)
(www.ebi.ac.uk/ena) as accession numbers ERS361826 to ERS379364, ERR1359331 to ERR485881,
ERS361826 to ERS379364, and SRR5853328 to SRR5858742 (listed in Data Sets S1 and S2 in the
supplemental material).
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